Generate:Biomedicines reveals GB-0895 data: ~98-day half-life, 6-month biomarker control

Generate Biomedicines, Inc.

Phase 1 (GB-0895-101): single 300 mg SC cuts BEC, FeNO, IL-5, IL-13 in mild-moderate asthma for ≥6 months; ~98-day half-life.
COPD Part C (N=40): biomarker reductions from Month 1 sustained ≥6 months; 300 mg comparable to 600 mg; no related SAEs.
Phase 3 trials SOLAIRIA-1 (NCT07276724) & SOLAIRIA-2 (NCT07359846) each N=786, severe uncontrolled asthma; primary endpoint AAER at 52 weeks.
GB-0895 well-tolerated: majority of TEAEs mild-moderate; all ISRs Grade 1; no anti-drug antibody impact on half-life.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.